



## **CRISPR Therapeutics to Present at the BMO Biopharma Spotlight Series: Gene Editing and Therapy**

**ZUG, Switzerland and BOSTON – September 29, 2022** -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the BMO Biopharma Spotlight Series: Gene Editing and Therapy on Thursday, October 6, 2022, at 9:00 a.m. ET.

A replay of the webcast will be archived for 14 days following the presentation on the “Events & Presentations” page in the Investors section of the Company’s website at <http://ir.crisprtx.com/events>.

### **About CRISPR Therapeutics**

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit [www.crisprtx.com](http://www.crisprtx.com).

CRISPR THERAPEUTICS® word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

#### **Investor Contact:**

Susan Kim  
+1-617-307-7503  
[susan.kim@crisprtx.com](mailto:susan.kim@crisprtx.com)

#### **Media Contact:**

Rachel Eides  
+1-617-315-4493  
[rachel.eides@crisprtx.com](mailto:rachel.eides@crisprtx.com)

###